Clinical Education InitiativeMenu
Search
Home > Courses > ACTHIV 2016 Conference - The Door is Open PrEP in Practice

ACTHIV 2016 Conference - The Door is Open PrEP in Practice

ACTHIV 2016 Conference - The Door is Open PrEP in Practice
ACTHIV 2016 Conference - The Door is Open PrEP in Practice
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Resource ID: CM413
Original Presentation: 4/29/2016
Web Posting: 9/15/2016
CE Expiration: 09/15/2017

The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 10th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 28-30, 2016 in Dallas, TX. The Conference was supported by funding from the Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course post-test quiz and follow the instructions.

FACULTY:
Antonio E. Urbina, MD, is the Medical Director for the Mt. Sinai Institute for Advanced Medicine/Spencer Cox Clinic and Mt. Sinai Downtown clinic in New York City. Dr. Urbina serves as a Medical Director for the Clinical Education Initiative of the New York State Department of Health AIDS Institute as well as Associate Professor of Medicine at the Icahn School of School of Medicine at Mount Sinai.

Estimated time to complete: 30 minutes

TARGET AUDIENCE
Physicians (both specialists and primary care/family medicine), nurse practitioners, and nurses who are frontline providers of care to persons at risk of or with HIV infection. Physician assistants, pharmacists, case managers and other healthcare professionals may also participate.

Learning Objectives
As a result of participating in this activity, participants should be better able to:

  • Discuss the latest data demonstrating how PrEP works across different patient populations
  • Describe the basic infrastructure elements needed to assure a successful PrEP program, and
  • Provide practical solutions to address common barriers to PrEP

ACCREDITATION

Physicians:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV). William Beaumont Hospital is accredited by the ACCME to provide continuing medical education for physicians.

William Beaumont Hospital designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners:

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 0.5 contact hours (0.5 pharmacotherapeutic contact hours).

Physician Assistants:

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category I credit for completing this program.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT

In order to obtain your certificate of credit, you must:

  • read the CME/CE information and review the full content of the activity
  • achieve a passing grade on the post-test (75% or greater), and
  • complete the evaluation.

Your certificate for the activity will be made available immediately to print online.

DISCLOSURES

According to the disclosure policy of Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, ACTHIV or the American Nurses Credentialing Council’s Commission on Accreditation. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity will contain discussion of off-label material.

Faculty Disclosure

Antonio E. Urbina, MD discloses the following relevant financial relationships: Advisory Board: Gilead Sciences, Merck & Co., Theratechnologies

Planner Disclosures

The following planners have indicated they have no relevant financial relationships to disclose: Bruce Agins, MD; John T. Brooks, MD; Courtney Fletcher, PharmD; Monica Gandhi, MD, MPH; John JD Juchniewicz, MCIS, CHCP; Natalie Kirkwood, RN, BSN, JD; Edward Moylan, RP; Tonia Poteat, PhD, MPH, PA-C; Asa E. Radix, MD, MPH; Cheryl Smith, MD; Brooke J.Taylor, MPH, CHCP; Barbara A. Young, MSW, LCSE, LCADC, SAC.

The following planners have indicated they have relevant financial relationships to disclose:

Laura Armas-Kolostroubis, MD - Advisory Board: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Theratech; Grant Recipient/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck & Co., ViiV Healthcare; Promotional Speakers Bureau: Gilead Sciences
Roger Bedimo, MD, MS - Advisory Board: Bristol-Myers Squibb, Merck & Co., Theratechnologies; Grant Recipient/Research Support: Bristol-Myers Squibb, Merck & Co.
Elizabeth Connick, MD - Data Safety Monitoring Board: City of Hope, Sangamo Biosciences
Carlos del Rio, MD - Consultant: InnaVirVax; Board Member: HIVMA, IAS-USA
Donna Futterman, MD - Grant Recipient / Research Support: Gilead Sciences
Joel Gallant, MD, MPH - Advisory Boards: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare; Grant Recipient / Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., Sangamo BioSciences, ViiV Healthcare
Rajesh Gandhi, MD - Grant Recipient / Research Support: EBSCO, Gilead Sciences, Merck & Co., Roche, ViiV Healthcare
Sharon Hillier, PhD - Advisory Board: Merck & Co., Perrigo, Symbiomix; Consultant: Merck & Co., Symbiomix; Grant/Research Support: Symbiomix
Peter Hunt, MD - Advisory Board: Merck & Co.; Consultant: Gilead Sciences, Merck & Co., ViiV Healthcare; Honoraria (non-promotional lectures on immune activation): Gilead Sciences, Janssen Therapeutics
Harry Lampiris, MD - Consultant: GLG Consultants
Sharon Lee, MD - Advisory Board: Gilead Sciences, ViiV Healthcare
Vincent Lo Re, MD, MSCE - Advisory Board: Gilead Sciences, ViiV Healthcare; Grant / Research Support: AstraZeneca
Michael J. Mugavero, MD, MHSc - Advisory Board / Consultant: Bristol-Myers Squibb, Gilead Services, Merck Foundation; Board of Directors: HarborPath; Grant / Research Support: Bristol-Myers Squibb
Renslow Sherer, MD - Advisory Board: Gilead Sciences; Grant Recipient/Research Support: Gilead Sciences, Janssen Therapeutics
William R. Short, MD, MPH - Advisory Board: Gilead Sciences, Janssen Therapeutics; Consultant: Gilead Sciences; Promotional Speakers Bureaus: Gilead Sciences, Janssen Therapeutics
Kathleen E. Squires, MD - Advisory Board: Gilead Sciences, Janssen Therapeutics, Bristol-Myers Squibb, Merck & Co., ViiV Healthcare; Consultant: Merck & Co.; Grant Recipient / Research Support: Gilead Sciences
Melanie Thompson, MD - Grant Recipient/Research Support: Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Research Laboratories, Pfizer Roche Diagnostics, TaiMed, Inc., ViiV Healthcare
Andrea Weddle, MSW - Advisory Board (ACA): Janssen Therapeutics

Privacy Policy
For more information about Beaumont’s privacy policy, please access http://www.beaumont.edu/privacy-policy
For more information about Academy privacy policy, please access http://www.academycme.org/privacy.htm

For CME information or credit details, contact: cme@beaumont.edu

For CNE information or credit details, contact: CEservices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2015. American Academy of CME, Inc., William Beaumont Hospital, and American Conference for the Treatment of HIV.

Bibliographic Sources:

Presenter
  • Antonio E. Urbina, MD
    Associate Professor of Medicine, Icahn School of Medicine
    Mount Sinai Hospital
    Medical Director, 275 7th Avenue and 230 West 17th Street Clinics
    Mt. Sinai Institute for Advanced Medicine
Presenter Bio
Antonio Urbina, MD
Dr. Antonio E. Urbina is a Medical Director for the Mt. Sinai Institute for Advanced Medicine in New York City. He also serves as a Medical Director/PI for the Clinical Education Initiative of the New York State Department of Health AIDS Institute as well as Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Since completing his residency in Internal Medicine at Saint Vincent Catholic Medical Center-Manhattan in 1995, Dr. Urbina has pioneered innovative educational programming for community-based clinics, hospitals, and public health departments. He has directed more than 10 HIV clinical trials research protocols. From 2007 to 2009, Dr. Urbina served on the Presidential Advisory Council on HIV/AIDS (PACHA) and recently completed his tenure on Governor Cuomo’s Task Force to end the AIDS epidemic in New York State.n the Presidential Advisory Council on HIV/AIDS (PACHA) as well as Governor Cuomo’s Task Force to end the AIDS epidemic in New York State.